Navigation Links
Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Date:11/3/2008

and in those undergoing major orthopedic surgery, treatment and secondary prevention of VTE, and acute coronary syndromes (ACS).

About Atrial Fibrillation

Atrial fibrillation (AF) is a major cause of hospitalization and mortality and affects about 2.5 million people in the United States, as well as 4.5 million people in the European Union and is emerging as a growing public health concern due to an aging population. In atrial fibrillation, some blood inside the atria may stagnate, and clots may form. If a piece of the clot breaks off and subsequently blocks an artery in the brain, a stroke results. According to the joint ACC/AHA/ESC guidelines for the management of atrial fibrillation, patients with atrial fibrillation have a two- to seven-fold increased risk of stroke and also have an increased risk of death and cardiovascular complications, including myocardial infarction.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concept that are engineered to provide significant advances over current treatments for cardiovascular and inflammatory diseases and cancer.

Portola's two lead Phase II compounds, betrixaban, an oral Factor Xa inhibitor and PRT060128, an ADP receptor antagonist, target the global multi- billion dollar antithrombotic market. Both product candidates have best-in- class features versus current and novel agents in development, addressing the hospital, specialty, and chronic care markets. The Company's earlier-stage programs are leveraging its chemistry and kinase expertise to develop specific Syk and JAK inhibitors to treat cancer and inflammatory diseases with broader activity. The company also has a novel anticoagulant antidote program with the potential to help manage the more than 20 million patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and cryopreservation ... for cells and tissues  ("BioLife" or the "Company"), today announced ... on May 4, 2015 (the "Annual Meeting"). Because ...
(Date:12/24/2014)... Missouri (PRWEB) December 23, 2014 GMO corn ... company, Syngenta, are in the process of being consolidated in ... is In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... of Kansas. , Management of the Syngenta GMO corn multidistrict ...
(Date:12/24/2014)... 23, 2014 SoundConnect’s ... introduce cutting edge communication technology, provide continued education ... This webinar series demonstrates online communication features and ... web conferencing’s most innovative and powerful tools. , ...
(Date:12/24/2014)... According to Ross Selinger, President of Selinger ... the national office market continues to be strong, driven by ... by the third quarter’s surprising 3.9% GDP, unemployment decreasing to ... have held inflation down and the Fed is keeping interest ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; ... (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { //s ...
... by University of Notre Dame physicist Boldizsr Jank and ... mystery in chemical physics. More than a century ago, ... Prize-winning physicist Neils Bohr predicted so-called "quantum jumps." He ... making transitions between discrete energy levels of individual atoms ...
... -- Researchers at Ohio State University have demonstrated the ... of electrons to read and write data. An ... data in less space, process data faster, and consume ... the journal Nature Materials , Arthur J. Epstein ...
Cached Biology Technology:FDA Grants Approval of ella(R) for Emergency Contraception 2FDA Grants Approval of ella(R) for Emergency Contraception 3FDA Grants Approval of ella(R) for Emergency Contraception 4FDA Grants Approval of ella(R) for Emergency Contraception 5FDA Grants Approval of ella(R) for Emergency Contraception 6FDA Grants Approval of ella(R) for Emergency Contraception 7New paper offers breakthrough on blinking molecules phenomenon 2Researchers successfully test new alternative to traditional semiconductors 2Researchers successfully test new alternative to traditional semiconductors 3
(Date:12/22/2014)... 22, 2014  The 2014 Holiday Season may be the ... Intelligence reports that the long anticipated floodgates for consumer ... demand for smart phones, tablets, and wearable mobile devices ... 2.5 billion users with nearly 4.8 billion biometric devices ...
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has announced the ... Button Synaptics Fingerprint Sensor Technology Analysis" report to ... Based on a totally different sensing technology ... time a fingerprint sensor in its product. ...
(Date:12/17/2014)... is fundamentally transforming the travel experience and nowhere is ... past decade, ePassports, biometric readers, and secure document scanners ... control via eGates and Automated Passport Control (APC) Kiosks ... borders across the globe. According to ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... Leadership in Technology and Innovation in Global BiometricsGAITHERSBURG, ... LMT ) has been named the Biometrics ... and Sullivan, recognizing the Corporation,s leadership in developing ... customers. Frost and Sullivan based the award on ...
... CEL-SCI Corporation (NYSE Alternext US: CVM) announced ... manufacturing process that could allow drugs developed using stem ... and thereby potentially also their shelf life. The ... also significantly accelerate the time to market by eliminating ...
... at the University of Florida have introduced ,Delicious, a ... yields, and is disease-resistant. The black fruit features exceptional ... well-suited for fresh fruit consumption and the potential for ... the comments of vineyard visitors who sampled the fruit., ...
Cached Biology News:Lockheed Martin Named Biometrics 'Company of the Year' by Frost and Sullivan 2CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 2CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 3CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 4
... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
... Perhaps sheer in-house demand is causing shortages in ... antibody. This can cause unwanted distractions, problems and ... for your hard work and endeavour! Bring us ... and market it internationally. We work under ISO ...
Topoisomerase I...
...
Biology Products: